PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): A phase II clinical trial Meeting Abstract
| Authors: | Stone, R. M.; Klimek, V.; DeAngelo, D. J.; Nimer, S.; Estey, E.; Galinsky, I.; Neuberg, D.; Yap, A.; Fox, E. A.; Gilliland, D. G.; Griffin, J. |
| Abstract Title: | PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): A phase II clinical trial |
| Meeting Title: | 44th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 100 |
| Issue: | 11 Pt. 1 |
| Meeting Dates: | 2002 Dec 6-10 |
| Meeting Location: | Philadelphia, PA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2002-11-01 |
| Start Page: | 86A |
| Language: | English |
| ACCESSION: | WOS:000179184700317 |
| PROVIDER: | wos |
| PUBMED: | 12448415 |
| Notes: | Meeting Abstract: 316 -- 44th Annual Meeting of the American-Society-of-Hematology -- DEC 06-10, 2002 -- PHILADELPHIA, PENNSYLVANIA -- 1 -- Source: Wos |
Citation Impact
Related MSK Work